@WHO: Subject to regulatory approvals, this agreement will give selected generic manufacturers the opportunity to develop, manufacture & supply generic versions of CAB-LA, in 90 low- & middle-income countries. It's a 🔑 step to support long-term access to this #HIV prevention option. https://t.co/SqRbRus1Vf

http://twitter.com/WHO
via IFTTT